Discovery of a potent, Highly selective, and In vivo anti-inflammatory Efficacious, P2Y 6 R antagonist with a novel quinoline-pyrazole scaffold

Yabiao Zhao,Bingqian Han,Zhiyi Wei,Yuanzhe Li,Yongfang Yao,Chuanjun Song,Yongtao Duan
DOI: https://doi.org/10.1016/j.ejmech.2024.116890
IF: 7.088
2024-09-28
European Journal of Medicinal Chemistry
Abstract:The P2Y 6 receptor (P2Y 6 R), as a crucial member of the purine family, is a potential therapeutic target for the treatment of intestinal inflammation, tracheal inflammation and diabetes. We first discovered the hit compound ( 5a, IC 50 = 168.5 nM against P2Y 6 R) through our in-house library screening. Then, further medicinal chemistry efforts were made to optimize compound 5a, and a potent P2Y 6 R antagonist ( 5 ab ) with better antagonistic activity (IC 50 = 19.6 nM) was obtained. The molecular docking, CETSA, SPR and pull-down results indicated that compound 5 ab displayed strong binding to P2Y 6 R. Also, compound 5 ab possessed high selectivity and satisfying oral bioactivity and pharmacokinetic profiles. In experiments with LPS-induced acute lung injury in mice, after treatment with compound 5 ab , the level of inflammatory factors IL-6, TNF-α and IL-β were considerably decreased, the infiltration of immune cells was decreased. Further exploration revealed that 5 ab inhibited the expression and release of chemokines in lung tissue, suppressing the activation of the NLRP3 inflammasome. Compound 5 ab had certain anti-inflammatory abilities in vivo and in vitro . These results demonstrate that compound 5 ab is a potential P2Y 6 R antagonist and is worthy of further study.
chemistry, medicinal
What problem does this paper attempt to address?